TOYOPEARL® MX-Trp-650M Mixed-Mode Resin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL® MX-Trp-650M Mixed-Mode Resin


TOYOPEARL® MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks.

TOYOPEARL® MX-Trp-650M is based on a rigid methacrylic polymer matrix, which provides excellent pressure/flow properties and allows high flow rates at large scale. Its ligand, the amino acid tryptophan, provides ionic and hydrophobic interactions. TOYOPEARL® MX-Trp-650M combines the selectivity options of mixed-mode chromatography with the binding capacity of modern ion exchange resins. This new mixed-mode resin is well-suited for intermediate and polishing steps, such as aggregate removal in antibody purification, and for the purification of targets that are difficult to purify using common purification platforms.

For more information visit the website www.tosohbioscience.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here